# Advanced glycation and crosslink breakers Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition Type: Mechanism Updated: 2026-08-06 Canonical: https://heretic.bio/articles/advanced-glycation-and-crosslink-breakers.html > Advanced glycation end-products are crosslinks formed when sugars modify long-lived proteins; the dominant one, glucosepane, accumulates for decades and no human enzyme removes it. Every drug program, alagebrium, aminoguanidine, pyridoxamine, azeliragon, failed or stalled in the clinic, and the reported glucosepane-cleaving enzyme activity could not be reproduced. No approved therapy removes existing crosslinks; only formation can be slowed, mainly through glycemic control. ## Overview Non-enzymatic glycation — the Maillard reaction, first described by Louis Camille Maillard in 1912 — is the irreversible chemical modification of proteins, lipids, and nucleic acids by reducing sugars. Its end products (AGEs) accumulate over decades in long-lived structural proteins and are one of the few genuinely _cumulative, damage-based_ mechanisms of aging: the body has no efficient way to remove crosslinks like **glucosepane** once formed. Crosslinked extracellular matrix means stiff arteries, stiff skin, stiff lenses, and stiff kidneys — independent of atherosclerosis or inflammation. This is a "hard" damage-repair target in [Overview - Longevity Science](longevity-science-overview.html) terms: unlike signaling interventions (mTOR, AMPK), the goal is to remove accumulated molecular garbage. That framing matters because nearly every _consumable_ "anti-glycation" supplement on the market attacks formation, not the existing burden — and formation-blockers have a weak clinical track record. ## Chemistry: How AGEs Form Three-stage cascade (Li et al., _Front Cardiovasc Med_ 2025, doi [10.3389/fcvm.2025.1637252](https://doi.org/10.3389/fcvm.2025.1637252)): 1. **Early:** open-chain glucose/fructose carbonyl + free amine (Lys, Arg, N-termini) → reversible **Schiff base** → rearranges to more stable **Amadori products** (e.g., HbA1c is an Amadori product — the reason HbA1c works as a glucose-time-integral biomarker). 2. **Intermediate:** Amadori products degrade into reactive **dicarbonyls** — methylglyoxal (MGO), glyoxal, 3-deoxyglucosone. These are 100–1000× more reactive than glucose itself and are the main drivers of actual AGE formation. MGO is also a byproduct of glycolysis, which is why glycation proceeds even with perfect glycemic control. 3. **Advanced:** dicarbonyls react with Lys/Arg/Cys to form irreversible AGEs. Rate accelerants: hyperglycemia, oxidative stress (hence "glycoxidation"), renal impairment (AGE retention), inflammation. ### The major AGE species AGE | Chemistry | Crosslink? | Notes ---|---|---|--- **Glucosepane** | Lys–Arg crosslink, nonfluorescent | **Yes** | Dominant crosslink in human collagen/crystallin — 10–1000× higher tissue levels than other crosslinks (Wikipedia summary of primary lit) **Pentosidine** | Lys–Arg crosslink, fluorescent | Yes | Fluorescent — the species measured by skin autofluorescence; rises with age and diabetes **CML** (Nε-carboxymethyllysine) | Non-crosslink | No | Most quantitatively abundant AGE marker; also the main _dietary_ AGE marker **CEL** (carboxyethyllysine) | Non-crosslink | No | MGO-derived **MG-H1** (methylglyoxal hydroimidazolone) | Arg modification | No | Most abundant intracellular MGO adduct **Argpyrimidine** | Arg, nonfluorescent | No | MGO-derived, lens/renal accumulation Key citation: Bieme, Fried & Lederer established glucosepane as the dominant Maillard crosslink in human serum albumin and lens protein (_J Biol Chem_ 2002;277:24907–24915, PMID [11960990](https://pubmed.ncbi.nlm.nih.gov/11960990/)). ## Glucosepane: The Central Target Why glucosepane is the one that matters for longevity: * **Quantitatively dominant** among crosslinks in aged human tissue. * **Irreversible on physiological timescales** — no known human enzyme degrades it. Its accumulation in skin collagen rises several-fold from youth to old age because ECM collagen turns over on multi-decade timescales, so the damage _integrates_. * **Mechanistically potent** — a covalent Lys–Arg bridge between collagen strands directly reduces arterial compliance, increases LV afterload, contributes to hypertension and renal fibrosis, and stiffens the lens and skin. Two enabling tools finally cracked the field open: 1\. **2015 (Spiegel lab, Yale):** first practical total synthesis of glucosepane — previously researchers literally could not obtain the standard to study it. Conceived and funded through SENS-style damage-repair advocacy (Lifespan Research Institute lineage). 2\. **2020:** anti-glucosepane antibodies enabling direct detection of glucosepane in retinal tissue (Streeter et al., _ACS Chem Biol_ 2020;15:2655–2661). ### The breaker programs — an honest ledger Program | Approach | Outcome ---|---|--- **Alagebrium (ALT-711)** | Thiazolium salt AGE-crosslink breaker (Alteon) | The original hope. Phase 2 signals on arterial compliance and systolic BP were modest; development **abandoned ~2007** ; never translated. Vasan et al., _Arch Biochem Biophys_ 2003 (PMID [14568012](https://pubmed.ncbi.nlm.nih.gov/14568012/)) reviews the rationale and early data. Mechanism later questioned — thiazoliums may trap dicarbonyls rather than cleave existing crosslinks. **Aminoguanidine (pimagedine)** | Formation blocker (nucleophilic dicarbonyl trap) | Phase 3 diabetic nephropathy (ACTION II) **failed** — insufficient efficacy, safety signals. Development abandoned. **Pyridoxamine (Pyridorin)** | B6 vitamer, dicarbonyl scavenger | Extended clinical program in diabetic nephropathy; **never approved**. **Revel Pharmaceuticals** | Bacterial glucosepane-cleaving enzymes found via metagenomic screening (SENS/Spiegel lineage) | Licensed the Yale enzyme work. As of Fight Aging reporting (2021, with 2024 follow-up), the original Spiegel-lab glucosepane-breaking activity **could not be reproduced** ; Revel shifted to other targets. No clinical candidate exists. **Azeliragon (TTP488)** | RAGE antagonist | Phase 3 Alzheimer's (STEADFAST) **stopped for futility** , 2018. **FPS-ZM1, sRAGE decoys, AGE-targeted nanoparticles** | RAGE axis | Preclinical only (Li 2025 review). **Net position (2026):** there is no approved or late-stage clinical therapy that removes existing AGE crosslinks. The history is a chain of failures — formation-blockers (aminoguanidine, pyridoxamine), breakers (alagebrium), and receptor blockers (azeliragon) all died in the clinic. This is exactly the kind of target where the gap between mechanistic certainty (crosslinks accumulate and stiffen tissue) and intervention capability (nothing works yet) is widest. Treat any "AGE-breaking" supplement claim as false by default. ## Pathophysiology Beyond Stiffness AGEs act through two distinct channels: 1. **Biophysical:** direct ECM crosslinking → arterial stiffness (independent of plaque), decreased LV compliance, reduced skin elasticity, lens opacity, glomerular basement membrane thickening. 2. **Signaling:** AGE–**RAGE** axis → ROS generation, NF-κB and ERK1/2 activation → fibrosis, inflammation, vascular smooth muscle proliferation (Li 2025). RAGE is upregulated in diabetic and atherosclerotic tissue. Soluble RAGE (sRAGE) acts as a decoy and is studied as a biomarker. Correlations: tissue/serum glucosepane and CML track with diabetic retinopathy, nephropathy severity, and arterial stiffness; skin autofluorescence (a pentosidine-weighted readout) prospectively predicts cardiovascular events in diabetes and CKD cohorts. ## Dietary AGEs Exogenous AGEs (mainly CML) form in browning/high-heat cooking: grilling, roasting, frying, broiling. Animal data suggest meaningful absorption and tissue incorporation; human high-AGE vs low-AGE diet RCTs show modest changes in inflammatory and insulin-resistance markers — real but small, and no hard outcomes. Practical reduction (Uribarri et al., _J Am Diet Assoc_ 2010;110:911–916, PMID [20497781](https://pubmed.ncbi.nlm.nih.gov/20497781/)): \- Cook with **moist heat** (stewing, poaching, steaming) instead of dry high heat. \- Shorter cooking times, lower temperatures; acid marinades (vinegar, citrus) reduce formation. \- Highest-AGE foods: broiled/fried meats, roasted nuts, deep-browned baked goods, caramelized anything. \- Note the tension with nutrition dogma: seared meat and "crispy" textures are precisely the high-AGE preparation style. See 08 - Nutrition and Eating section for diet framing. The dominant _endogenous_ driver is still the glucose×time integral plus dicarbonyl load — which is why HbA1c-lowering (see [GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide)](glp-1-peptides-semaglutide-tirzepatide-retatrutide.html)) and possibly metformin (a direct methylglyoxal scavenger — one of its less-appreciated mechanisms) matter more than any food trick. DCCT "metabolic memory" — early glycemic control producing lasting complication reduction years later — is the strongest human evidence that glycation burden is causally load-bearing. ## Measurement Method | What it reads | Caveats ---|---|--- HbA1c | Amadori (early glycation) | Confounded by anemia, hemolysis, RBC turnover Skin autofluorescence (AGE Reader) | Fluorescent AGEs (pentosidine-weighted) | Non-invasive, prospective CV predictive value in DM/CKD; blind to nonfluorescent glucosepane Serum CML / MG-H1 ELISA | Abundant non-crosslink AGEs | Assay standardization poor; diet-confounded Glucosepane quantification | The real target | Requires collagen hydrolysis + LC-MS or the 2020 antibody tools — research-grade only No consumer test measures glucosepane. Claims otherwise are marketing. ## Skin and "Anti-Glycation" Cosmetics The 2025 comprehensive review of anti-glycation agents for skin (PMID [40298870](https://pubmed.ncbi.nlm.nih.gov/40298870/)) tabulates in-vitro/in-vivo evidence for carnosine, polyphenols, peptides, and synthetic inhibitors: overwhelmingly preclinical, with weak human trial data. Topical claims are built on formation-inhibition in fibroblast assays. Collagen _production_ can be stimulated (see [GHK-Cu (Copper Peptide)](ghk-cu-copper-tripeptide-gene-modulatory-regenerative-peptide.html)), but breaking existing dermal crosslinks topically is unsupported. Bryan Johnson's publicized observation that skin "papery" quality tracks AGEs while collagen is fixable is directionally consistent with the science. ## Where This Connects * [Overview - Longevity Science](longevity-science-overview.html) — damage-accumulation hallmarks * [Plasmalogens and Membrane Health](plasmalogens-and-membrane-health.html) — the other half of membrane/ECM lipid aging * [GHK-Cu (Copper Peptide)](ghk-cu-copper-tripeptide-gene-modulatory-regenerative-peptide.html) — collagen biology without crosslink breaking * [GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide)](glp-1-peptides-semaglutide-tirzepatide-retatrutide.html) — glycemic time-integral reduction * [Methylene Blue](methylene-blue.html) — oxidative-stress arm of glycoxidation * [Telomere Science](telomere-science.html) / [Alpha-Ketoglutarate (AKG) - The Metabolic Longevity Molecule](alpha-ketoglutarate-akg-the-metabolic-longevity-molecule.html) — contrasting signaling-vs-damage paradigms ## Open Questions 1. Do glucosepane-cleaving enzymes actually exist in environmental bacteria (the "graveyards are not sticky" argument), or is degradation carried by multi-enzyme consortia that don't reduce to a single drug? 2. Is arterial stiffening in aged humans dominated by glucosepane, or by elastin calcification/collagen isoform shifts? (No selective human tool has ever tested this.) 3. Would decades-long low-dose dicarbonyl scavenging (e.g., metformin's MGO trapping) measurably lower tissue glucosepane? Unstudied. 4. How much of the dietary AGE signal is cause vs marker of overall processed-food load? ## Notes * **Incentive audit:** "Anti-glycation" is a fully commercialized claim space (cosmeceuticals, carnosine/carnosinase supplements, "AGE-shielding" diets). Primary-source support is thin and formation-focused; existing-burden removal remains science fiction. * **Evidence discipline:** separate (a) crosslink _formation_ (druggable, weak clinical record), (b) crosslink _breaking_ (the real prize, zero clinical successes), (c) RAGE signaling (targetable, one phase-3 failure), (d) dietary exposure (modest RCT markers). Marketing conflates all four. _Primary sources: PMID[39141382](https://pubmed.ncbi.nlm.nih.gov/39141382/) & 20497781 & 14568012 & 40298870 & 11960990; doi [10.3389/fcvm.2025.1637252](https://doi.org/10.3389/fcvm.2025.1637252); doi [10.1001/jama.2024.11463](https://doi.org/10.1001/jama.2024.11463); Streeter ACS Chem Biol 2020;15:2655–2661; Antioxidants 2025;14:492._ ## Sources 1. DOI 10.3389/fcvm.2025.1637252 (DOI 10.3389/fcvm.2025.1637252) 2. PubMed 11960990 (PubMed 11960990) 3. PubMed 14568012 (PubMed 14568012) 4. PubMed 20497781 (PubMed 20497781) 5. PubMed 40298870 (PubMed 40298870) 6. PubMed 39141382 (PubMed 39141382) 7. DOI 10.1001/jama.2024.11463 (DOI 10.1001/jama.2024.11463)